Combined Activation of Murine Lymphocytes with Staphylococcal Enterotoxin and Interleukin-2 Results in Additive Cytotoxic Activity

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 1994 Apr 1

PMID 8168122

Citations 5

Authors

H Belfrage

P Bhiladvala

G Hedlund

M Dohlsten

T Kalland

Affiliations

Soon will be listed here.

Abstract

This report demonstrates that in vitro activation of murine spleen cells with interleukin-2 (IL-2) or the bacterial superantigen staphylococcal enterotoxin A (SEA) results in different patterns of activation and function of cytotoxic cells. Lymphokine-activated killer activity and antibody-dependent cellular cytotoxicity (ADCC) are mainly mediated by IL-2 activated natural killer (NK) cells. SEA is the most powerful T cell mitogen known so far and retargets cytotoxic T lymphocytes (CTL) to tumors expressing major histocompatibility complex (MHC) class II in staphylococcal-enterotoxin-dependent cellular cytotoxicity (SDCC). Culture of mouse spleen cells with SEA led to expansion and activation of T cells, which demonstrated strong SDCC activity and some NK-like cytotoxicity after 5 days in culture. Cell sorting revealed that both CD8+ and CD4+ T cells mediated SDCC but the former were more effective. Phenotypic analysis showed that SEA preferentially stimulated and expanded T cells expressing T cell receptor V beta 11, in particular CD8+ T cells. Combined activation with SEA and IL-2 resulted in simultaneous induction of T and NK cell cytotoxicity. Moreover, IL-2 had additive effects on SEA-induced SDCC. Combined treatment with SEA and IL-2 might therefore be an approach to induce maximal cytotoxicity against tumors and to recruit both T and NK cells in tumor therapy.

Citing Articles

Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis.

Matsuda K, Miyoshi H, Hiraoka K, Hamada T, Yoshida S, Ishibashi Y Clin Exp Med. 2018; 18(4):487-494.

PMID: 29961175 DOI: 10.1007/s10238-018-0515-4.

Enhancement of superantigen activity and antitumor response of staphylococcal enterotoxin C2 by site-directed mutagenesis.

Wang X, Xu M, Zhang H, Liu J, Li X, Zhang C Cancer Immunol Immunother. 2008; 58(5):677-86.

PMID: 18818919 PMC: 11030829. DOI: 10.1007/s00262-008-0590-6.

Synovial fibroblasts as target cells for staphylococcal enterotoxin-induced T-cell cytotoxicity.

Kraft M, Filsinger S, Kramer K, Kabelitz D, Hansch G, Schoels M Immunology. 1998; 93(1):20-5.

PMID: 9536114 PMC: 1364101. DOI: 10.1046/j.1365-2567.1998.00398.x.

Mycoplasma arthritidis mitogen up-regulates human NK cell activity.

DOrazio J, Cole B, Stein-Streilein J Infect Immun. 1996; 64(2):441-7.

PMID: 8550189 PMC: 173783. DOI: 10.1128/iai.64.2.441-447.1996.

Enhanced and prolonged efficacy of superantigen-induced cytotoxic T lymphocyte activity by interleukin-2 in vivo.

Belfrage H, Dohlsten M, Hedlund G, Kalland T Cancer Immunol Immunother. 1995; 41(2):87-94.

PMID: 7656274 PMC: 11037810. DOI: 10.1007/BF01527404.

References

MacDonald H, Baschieri S, Lees R . Clonal expansion precedes anergy and death of V beta 8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur J Immunol. 1991; 21(8):1963-6. DOI: 10.1002/eji.1830210827. View

Jett J, Mantovani A, Herberman R . Augmentation of human monocyte-mediated cytolysis by interferon. Cell Immunol. 1980; 54(2):425-34. DOI: 10.1016/0008-8749(80)90222-1. View

Topalian S, Muul L, Solomon D, Rosenberg S . Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987; 102(1):127-41. DOI: 10.1016/s0022-1759(87)80018-2. View

Dohlsten M, Hedlund G, Kalland T . Staphylococcal-enterotoxin-dependent cell-mediated cytotoxicity. Immunol Today. 1991; 12(5):147-50. DOI: 10.1016/S0167-5699(05)80043-X. View

Fischer H, Dohlsten M, Andersson U, Hedlund G, Ericsson P, Hansson J . Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells. J Immunol. 1990; 144(12):4663-9. View

Hedlund G, Dohlsten M, Petersson C, Kalland T . Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol Immunother. 1993; 36(2):89-93. PMC: 11037945. DOI: 10.1007/BF01754407. View

Lando P, Hedlund G, Dohlsten M, Kalland T . Bacterial superantigens as anti-tumour agents: induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A. Cancer Immunol Immunother. 1991; 33(4):231-7. PMC: 11038019. DOI: 10.1007/BF01744942. View

Abe R, Vacchio M, Fox B, Hodes R . Preferential expression of the T-cell receptor V beta 3 gene by Mlsc reactive T cells. Nature. 1988; 335(6193):827-30. DOI: 10.1038/335827a0. View

Salup R, Mathieson B, Wiltrout R . Precursor phenotype of lymphokine-activated killer cells in the mouse. J Immunol. 1987; 138(11):3635-9. View

10.

Sensi M, Grazioli L, Rodolfo M, Parmiani G . Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors. Cancer Immunol Immunother. 1990; 31(1):37-43. PMC: 11038148. DOI: 10.1007/BF01742493. View

11.

Fischer H, Dohlsten M, Lindvall M, Sjogren H, Carlsson R . Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines. J Immunol. 1989; 142(9):3151-7. View

12.

Dohlsten M, Hedlund G, AKERBLOM E, Lando P, Kalland T . Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A. 1991; 88(20):9287-91. PMC: 52699. DOI: 10.1073/pnas.88.20.9287. View

13.

Yang J, Mule J, Rosenberg S . Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. J Immunol. 1986; 137(2):715-22. View

14.

Hedlund G, Dohlsten M, Herrmann T, Buell G, Lando P, Segren S . A recombinant C-terminal fragment of staphylococcal enterotoxin A binds to human MHC class II products but does not activate T cells. J Immunol. 1991; 147(12):4082-5. View

15.

Yui K, Komori S, Katsumata M, Siegel R, Greene M . Self-reactive T cells can escape clonal deletion in T-cell receptor V beta 8.1 transgenic mice. Proc Natl Acad Sci U S A. 1990; 87(18):7135-9. PMC: 54698. DOI: 10.1073/pnas.87.18.7135. View

16.

Baccala R, Kono D, Walker S, Balderas R, Theofilopoulos A . Genomically imposed and somatically modified human thymocyte V beta gene repertoires. Proc Natl Acad Sci U S A. 1991; 88(7):2908-12. PMC: 51349. DOI: 10.1073/pnas.88.7.2908. View

17.

Conkling P, Chua C, Nadler P, Greenberg C, Doty E, Misukonis M . Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. Cancer Res. 1988; 48(19):5604-9. View

18.

Tepper R, Pattengale P, Leder P . Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989; 57(3):503-12. DOI: 10.1016/0092-8674(89)90925-2. View

19.

Lefor A, Eisenthal A, Rosenberg S . Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts. J Immunol. 1988; 140(11):4062-9. View

20.

Marrack P, Kappler J . The staphylococcal enterotoxins and their relatives. Science. 1990; 248(4956):705-11. DOI: 10.1126/science.2185544. View